Across TCGA pan-cancer cohorts, RPP25 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RPP25 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPP25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPP25 expression acts as an unfavorable survival marker.
STAD are the cancer types where RPP25 Mutation most reproducibly stratifies survival.